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Edited by Patrick Aloy and Robert B. RussellAbstract The majority of drug-related toxicities are idiosyn-
cratic, with little pathophysiological insight and mechanistic
understanding. Pathway toxicology is an emerging ﬁeld of toxi-
cology in the post-genomic era that studies the molecular inter-
actions between toxicants and biological pathways as a way to
bridge this knowledge gap. Using two case studies – acetamino-
phen and p38 MAPK inhibitors – this review illustrates how a
pathway-based perspective has advanced our understanding of
compound and target-based toxicities. The advancement of path-
way toxicology will be dependent on integrated applications of
techniques from basic sciences and a fundamental understanding
of the interdependence of multiple biological pathways in living
organisms.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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toxicity1. Introduction
In the US alone there are 2.1 million drug-related injuries
and 100000 deaths per year [1]. The vast majority of these
drug-related toxicities are idiosyncratic, with little pathophys-
iological insight and mechanistic understanding. This apparent
gap has triggered us to examine how a new perspective in Tox-
icology can provide us with greater insight in mechanisms of
toxicity. Indeed, the history of Toxicology has evolved from
a descriptive to mechanistic science, with new understandings
provided by seminal breakthroughs in biology and medicine
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,ieties. Puof a ‘‘toxicon’’, the toxic agent, as a chemical entity. In the
1940s, Elizabeth and James Millers work demonstrated that
the human body converts the initial toxicon into metabolites,
many of which are responsible for initiating the toxic responses
in vivo [2]. Many current post-genomic technical advances
(gene knockouts, RNA interference, whole genome scans, gene
expression analysis, proteomics, metabonomics, and other
panomics) provided modern toxicologists an expanded view
of multiple interactions among molecular pathways. These
breakthroughs provided clear illustrations that while a given
toxicon may initially perturb primarily one biological path-
way, the interactions and interdependence of molecular path-
ways almost inevitably leads to downstream perturbation of
multiple signaling cascades with concomitant eﬀects on physi-
ologically relevant endpoints in the whole organism (Fig. 1).
This has signiﬁcant implications to our understanding of
mechanisms of drug-induced toxicity. In this review, we will
use two case examples to illustrate this point.2. Acetaminophen-induced liver toxicity, from a single
mechanism to multiple pathways
Acetaminophen, an non-steroidal anti-inﬂammatory drug
(NSAID), has been widely used for over 50 years in the treat-
ment of pain and fever and provides for the eﬀective relief of
these symptoms. It is safe when used at therapeutic doses.
However, overdose (either intentional or accidental) can lead
to serious and even fatal hepatotoxicity. In the US acetamino-
phen is responsible for up to 50% of all adult cases of acute li-
ver failure [3].
In the liver, acetaminophen is metabolized to the non-toxic
conjugated metabolites acetaminophen glucuronide and acet-
aminophen sulfate. These detoxiﬁcation pathways account
for over 90% of the acetaminophen metabolism by the liver.
Under normal conditions, less than 10% of the acetaminophen
is metabolized by the cytochrome P450 enzymes (primarily
CYP 2E1, 1A2, and 3A4) to produce a toxic metabolic interme-
diate called N-acetyl-p-benzoquinoemine (NAPQI). The small
amount of NAPQI formed is normally further detoxiﬁed by
intracellular glutathione. In the cases of high drug load (such
as intentional or accidental overdose), and/or low intracellular
glutathione reserve (such as after fasting or alcohol use), NAP-
QI can covalently modify thiol groups on cellular proteins. The
traditional thought is that such covalent protein adducts are the
cause of liver cell or hepatocyte injury [3]. However, it was dem-
onstrated that the generation of NAPQI is necessary but notblished by Elsevier B.V. All rights reserved.
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thsuﬃcient to account for acetaminophen-induced liver injury.
The m-hydroxy isomer of acetaminophen, 3 0-hydroxyacetani-
lide, is not hepatotoxic in mice, even though the amounts of
covalent binding are almost equivalent [4]. The covalent bind-
ing of 3 0-hydroxyacetanilide is also located in the centrilobular
hepatocytes, the area of the ensuing necrosis and covalent bind-
ing by the hepatotoxic isomer acetaminophen [5]. These and
other studies raised the possibility that the amount of covalent
binding is not a determinant of the ﬁnal toxicity outcome.
Recently, genomic, metabolomic and proteomic approaches
have been applied in the human hepatocyte chimeric mice
model to investigate the mechanisms and pathways of acetami-
nophen induced toxicity [6]. In this animal model, human
hepatocytes were transplanted into transgenic mice. The
replacement ratio of mouse liver with human liver in chimeric
mice was estimated at 75–95%, with human speciﬁc metabolic
responses to drugs observed. In acetaminophen-treated ani-
mals, perturbations in lipid metabolism, fatty acid transport,
and glycolysis indicated suppression of the b-oxidation path-
ways of fatty acids, leading to the depletion of acetyl-CoA.
Perturbations in the oxidative stress-related proteins such as
peroxiredoxin 1 and catalase, were observed. These ﬁndings
are in accordance with those observed in normal mice treated
with acetaminophen [7]. These data suggest that both intracel-
lular mitochondrial and oxidative stress pathways were per-
turbed by the treatment of acetaminophen.
The question still remains as to whether it was the parent
acetaminophen or the NAPQI metabolite responsible for the
observed changes in mitochondrial energy status and oxidative
stress. Data from the in vitro treatment of freshly-isolated
mouse hepatocytes have provided mechanistic insight [8]. In
this in vitro model, acetaminophen-induced cell death occursin two phases, a metabolic phase and an oxidative phase.
The metabolic phase occurs with NAPQI formation, glutathi-
one depletion and covalent protein binding. The oxidative
phase occurs with increased oxidative stress, loss of mitochon-
drial membrane potential, mitochondrial permeability transi-
tion, and resulting toxicity. The oxidative phase does not
require the presence of either acetaminophen or the NAPQI
metabolite, as addition of acetaminophen in the second phase
did not alter toxicity [8]. This study raised the interesting pos-
sibility that while both acetaminophen and 3 0-hydroxyacetan-
ilide can initiate a similar metabolic phase, acetaminophen is
unique in its ability to progress to the oxidative phase at least
in the mouse hepatocytes. Further pathway studies using these
two isomeric chemicals and the mouse hepatocyte model are
required to delineate the diﬀerences in the triggering events
leading the metabolic phase to oxidative phase.
In addition to these in vitro studies, a series of knock out mice
were used to investigate their susceptibility to acetaminophen in-
duced hepatotoxicity (e.g., reviewed by Kaplowitz [9]). Not sur-
prisingly, cytochrome 2e1 and 1a2 null mice oﬀered protection
against acetaminophen toxicity, indicating the importance of
the metabolic phase [10]. Glutathione synthesis and detoxiﬁca-
tion enzymes are regulated by the transcription factor Nrf2,
and Nrf2 null mice are more susceptible to acetaminophen tox-
icity [11]. Interestingly, several key proteins in the cytokine fam-
ily and the innate immune system have emerged as important
modulators of the progression and severity of organ damage.
Interferon, Fas or Fas ligand null mice are resistant, while inter-
leukin-10 and -6 null mice are susceptible to acetaminophen tox-
icity. In most of these knockout models, alterations in toxicity
were not associated with changes in the amount of covalent
binding or glutathione depletion (reviewed by Kaplowitz [9]).
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Fig. 2. Acetaminophen-induced toxicity. A pathway toxicologist perspective on acetaminophen-induced liver injury. Please see the main text for
abbreviations.
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stream modulators of acetaminophen toxicity.
Recently, the c-Jun N-terminal kinase (JNK) was found to
play a major role in murine acetaminophen hepatotoxicity
[12]. Chemical inhibitors of JNK, leﬂunomide or A77 1726
protected acetaminophen-induced cell injury through inhibi-
tion mitochondrial permeability transition in immortalized hu-
man hepatocytes [13]. This work suggest that JNK acts
downstream of acetaminophen metabolism to promote hepa-
totoxicity. Whether this ties into tumor necrosis factor
(TNF) and NFkB pathways is an open question [14]. These
ﬁndings also suggest that other stress kinases involved in cyto-
kine responses may also be critical to the ﬁnal manifestation of
acetaminophen toxicity. In other parallel work, it was reported
that delivery of nitric oxide (NO) in small amounts to the liver,
via a novel derivative of the bile acid ursodeoxycholic acid, re-
sulted in signiﬁcant protection of the liver from acetamino-
phen-induced damage. NO appears to produce these
beneﬁcial actions through several mechanisms, including the
suppression of synthesis of several proinﬂammatory cytokines
[15]. Most recently, in a toxicogenomics study that examined
the gene expression levels in blood cells from rats treated with
acetaminophen, the most signiﬁcant biological discriminator
between non-toxic and toxic groups of animals were genes in-
volved in inﬂammatory processes [16].
Therefore, acetaminophen is a classic example of a well-
studied drug starting with the understanding of a single path-
way (i.e., the metabolic activation by the cytochrome P450s),
to multiple pathways involving a metabolic phase, an oxidative
phase, several cytokines of the innate immune system, and
stress kinases critical in the regulation of cytokine responses
(Fig. 2). Currently a collective body of in vitro and in vivo evi-
dence suggests that multiple phases or steps of acetaminophen-induced liver injury are in line with the delayed on-set of liver
injury biomarkers by acetaminophen treatment [17]. It is antic-
ipated that this well-studied drug will continue to be an excel-
lent model system for exploring pathway toxicology.3. An emerging area of pathway understanding: p38 inhibitors
SB-202190 was discovered as a potent inhibitor of IL-1 and
TNF production in human monocytes. Subsequent identiﬁca-
tion of p38 as its target [18] has spawned an on-going race to
develop safe, orally-available, small molecule inhibitors of p38
to combat chronic inﬂammatory diseases such as rheumatoid
arthritis. To date, over 20 compounds have entered clinical tri-
als with no small molecule inhibitors making it to the market
[19]. Most discontinued p38 inhibitors have failed due to safety
concerns, most notably elevated liver enzymes and skin rash
(VX-745 was discontinued due to undisclosed CNS toxicity
[20]). Relatively little is known about the link between p38
and reported adverse events. However, the almost ubiquitous
role for p38 in cellular regulation in multiple cell types present
unique opportunities to understand pathway biology of p38
modulation.
The p38 stress activated protein kinases are involved in reg-
ulating cell growth, cell diﬀerentiation, proliferation, apopto-
sis and response to inﬂammation and stress [21]. The p38
family of protein kinases is regulated by multiple upstream
kinases, MKK3, MKK6 and MKK4, in response to cellular
stress, toll-like receptor ligands and IL-1, among others.
There are four highly-related p38 isoforms (a, b, d, and c)
with distinct tissue expression patterns. p38a and b are ex-
pressed in most tissues including human lymphoid tissues,
leukocytes, pancreas and liver, while c and d have a more
J.J. Xu et al. / FEBS Letters 582 (2008) 1276–1282 1279limited distribution including skeletal muscle, heart lung, thy-
mus and testis [20]. The a and c isoforms are predominantly
expressed and activated in inﬂammation, localized to macro-
phages in the synovial lining and blood vessels [22]. Addition-
ally, roles for a, b, and d in the skin have also been
elucidated [23].
3.1. p38 and the liver
Elevated liver enzymes in human plasma have been reported
for VX-745, BIRB 796 [20,24] and AMG-548 [25]. On-going
research has demonstrated the role of p38 in a multitude of
liver cell functions, including extracellular matrix production,
growth regulation, cell volume regulation, ion and bile salt
transport, gluconeogenesis and lipogenesis. Whether these
functional roles of p38 are mechanistically linked to elevated
liver enzymes in human plasma with p38 inhibitors is an open
question.
Liver ﬁbrosis is characterized by a deposition of extracellular
matrix proteins as part of excessive wound healing in response
to chronic stimuli. As part of this response, signaling from p38,
and focal adhesion kinase-phosphatidylinositol 3-kinase-Akt-
p70 S6 kinase (FAK-PI3K-Akt-S6K) cascades regulate the
proliferation, cell cycle progression as well as collagen gene
expression in activated hepatic stellate cells [26]. p38 signaling
has been found to regulate a1 collagen gene expression by tran-
scriptional activation and by increasing mRNA stability,
thereby contributing to increased synthesis and deposition of
type I collagen [26].
p38 has been demonstrated to play a role in growth regula-
tion, mediating growth inhibitory eﬀects in developing rat
hepatocytes, as demonstrated via treatment with SB203580, a
small molecule p38 inhibitor [27,28]. PGC-1a and peroxisome
proliferator-a (PPARa) are downstream targets of p38 [29,30].
p38 phosphorylates the A/B domain of PPARa at Ser 6, 12
and/or 21 [30]. PPARa directly regulates genes that are in-
volved implicated in the response to peroxisome proliferators,
altering expression of cell cycle regulatory proteins, cell prolif-
eration and apoptosis [31,32]. Thus, survival signaling medi-
ated by p38 via PPARa may provide a link between p38
inhibition and necrotic and/or apoptotic liver injury.
In addition to proliferative changes, liver regeneration and
cholestasis are associated with adaptive changes in expression
of gap and tight junctions. During hepatocyte regeneration fol-
lowing partial hepatectomy, dynamic changes in the formation
of gap and tight junctions were, in part, regulated by p38 and
independent of cell growth [33]. Changes in expression and
function of the gap junction protein, Cx32, and tight junction
protein, claudin-1, were observed following SB203580 treat-
ment [34].
Failure to regulate liver cell volume has been associated with
liver cell injury resulting from alcohol, ischemia/reperfusion,
and organ preservation [35–37]. In hepatocytes non-selective
cation channels play a critical role in the maintenance of cell
volume, many of which have been demonstrated to be under
the inﬂuence of p38. Hypotonic exposure led to increased cell
volume and increased p38 activity in a HTC rat hepatoma cell
line [38]. Constitutive p38 activity was demonstrated to be in-
volved in sustaining the low Na+ permeability required for
maintenance of cell volume. Na+ currents could be increased
by inhibiting p38 activity with SB203580 [38]. In perfused rat
liver, treatment with SB203580 has also been used to demon-
strate the role of p38 in response to hypo-osmotic exposurevia regulation of cell volume regulation [39]. Swelling-induced
activation of p38 is involved in volume regulatory K(+) eﬄux
in liver [39]. Further roles in regulating ion transport were elu-
cidated with SB202190, demonstrating that liver plasma vesi-
cles puriﬁed in the presence of SB202190 had lost the ability
to accumulate Mg(2+) in exchange for intra-vesicular Na(+),
following activation of protein kinase C signaling [40].
Complementing the role in ion transport, p38 also indirectly
regulates bile salt transport. Traﬃcking of the bile salt export
pump (BSEP) from the Golgi to the canalicular membrane has
been shown to be regulated via p38 signaling in rat hepatocytes
[41]. Consequently, tauroursodesoxycholate (TUDC)-induced
choleresis was demonstrated to be under the dual control of
p38 and extracellular regulated kinase (ERK) regulation.
SB202190 abolished the stimulatory eﬀect of TUDC on tauro-
cholate excretion in perfused rat liver [42].
Finally, p38 regulates both lipo- and gluconeogenic aspects
of hepatocyte metabolism. Hepatic lipogenesis is the principal
route for the conversion of excess carbohydrates into fatty
acids and, upon dysregulation, leads to fatty liver. This process
is coordinately regulated by insulin and glucagon, playing
stimulatory and inhibitory roles, respectively. Following p38
inhibition, levels of plasma triglyceride and triglyceride accu-
mulation in the liver were elevated in mice [43]. Expression
of essential lipogenic genes (SREBP-1, fatty acid synthase, hy-
droxyl-3-methylglutaryl coenzyme A reductase, farnesyl pyro-
phosphate synthase and cytochrome P-450-51) were increased
following p38 inhibition in primary hepatocytes. p38 activa-
tion was shown to inhibit insulin-induced lipogenic genes.
Insulin-induced expression of the PGC-1b gene, a key coacti-
vator of SREBP-1c, was enhanced by p38 inhibition and sup-
pressed by p38 activation [43].
Similarly, p38 has been identiﬁed as a critical signaling
component in free fatty acid induced transcription of glucone-
ogenic genes. p38 activation was shown to be necessary for
mid- and long-chain fatty acid induced transcription of
PGC-1a and CREB, known gluconeogenic regulators [44].
Inhibition of p38 suppressed gluconeogenesis in liver along
with key gluconeogenic genes, including phosphoenolpyruvate
carboxykinase and glucose-6-phosphatase. Furthermore, p38
inhibition prevented PGC-1a transcription and CREB phos-
phorylation [45].
3.2. p38 and the skin
The seemingly ubiquitous role of p38 in liver cell regulation
is perpetuated with multiple functions of p38 in skin physiol-
ogy. Consequently, p38 has been proposed as a target for some
disorders (psoriasis, contact hypersensitivity and dermal ﬁbro-
sis, for example [46]) and yet may prove to be a liability for
others, such as rheumatoid arthritis. For example, in the Phase
II study of VX-702 for rheumatoid arthritis, 9% of patients
presented with some type of skin disorder [47]. Similarly, Pﬁz-
ers Phase I clinical studies with SD-0006 reported adverse ef-
fects on the skin, among others (abstract refer #33 in [48]). As
with the liver, repeated ﬁndings of skin disorders prompted the
question of whether there might be a mechanistic connection
underlying these ﬁndings and motivate pathway-based investi-
gation into the putative side eﬀects of excessive p38 inhibition.
The skin is a highly dynamic organ that requires the carefully
choreographed proliferation and diﬀerentiation of keratino-
cytes and sebocytes as well as the interplay with several other
inﬁltrating cell types. Several aspects of keratinocyte function
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the stress response to UV, hydrogen peroxide or inﬂammatory
cytokines (TNF or IL-1b) was demonstrated with SB203580
[49]. Further, the family of PPARs has opposing eﬀects on the
proliferation and diﬀerentiation of keratinocytes, mediated in
part by upstream p38 [50]. Expression of keratinocyte diﬀeren-
tiation markers, transglutaminase-1, loricrin, and involucrin
were all inhibited by SB202190 and SB203580 [51]. Similarly,
sebocyte diﬀerentiation, proliferation and sebum production
are under PPAR control [50,52], implicating a potential role
for p38 in acne and other related skin pathology.
Epidermal wound healing involves both a proliferative and
migratory component. In addition to the well known role of
the epidermal growth factor receptor (EGFR)/extracellular
regulated kinase (ERK) pathway in skin and skin rash, as dem-
onstrated with EGFR inhibitors [53], p38 has been found to
coordinate with ERK to regulate the cellular migration and
proliferation in epithelial wound healing [54,55]. p38 is thought
to be involved in the propagation of injury related signaling
[56], with p38a and p38d speciﬁcally regulating invasion and
growth in head and neck squamous carcinoma cells [57]. p38
activity was demonstrated to be a necessary but insuﬃcient
component of keratinocyte migration, as inhibition was able
to abrogate keratinocyte migration on collagen surfaces but
activation was not able to initiate migration [58].
Finally, in the context of acne and cell migration, the
destruction of collagen matrices and interaction of multiple
cell types is a necessary step for the spread of inﬂammation.
The interaction of keratinocytes and ﬁbroblasts regulate re-
lease of matrix metalloproteinases (MMPs), MMP-2 and
MMP-9, and their inhibitors (TIMPs) [59]. The origin of
MMPs and TIMPs in serum is attributed to keratinocytes
and sebocytes and those of epithelial origin may be involved
in acne pathogenesis by mediating rupture of the pilosebaceous
follicle [60,61]. p38 is involved in the stimulation of MMP-9 by
TNF in human monocytes. SB203580 treatment downregu-Na+/K+
transport BSEP
p38
cell volume 
regulation
gluconeogenesis bile
transport
Liver Effects
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ig. 3. Putative mechanistic roles of p38 in the liver and skin. Multiple eﬀ
echanistic hypotheses linking p38 inhibition with organ level eﬀects.lated both MMP-9 and TIMP-1 levels, indicating that p38
plays a dual role, regulating the MMP/TIMP balance [62].
3.3. Outlook for p38 inhibitors
There are many potential pathway-based mechanistic links
between p38 and adverse events in the liver and skin
(Fig. 3). If proven to be relevant in vivo, it will be necessary
to determine the reversibility and dose–response relation-
ships for side-eﬀects in relation to eﬃcacy endpoints in
order to determine if suﬃcient therapeutic windows exist.
The ability to understand pathway-based toxicities as a
result of p38 inhibition and the ability to circumvent unde-
sirable side eﬀects, possibly via careful selections of com-
pounds with suﬃcient therapeutic window and dosing
regimens in the clinic, will likely dictate the future success
of this new class of compounds. Furthermore, understanding
of mechanism and pathway-based toxicology will beneﬁt
drug discovery more broadly, enabling the development
and implementation of assays to screen out these liabilities
earlier in the process.4. Towards a pathway toxicology
Modern drug therapies have saved, extended, and improved
many lives. However, our society is aﬀected by adverse events
due to idiosyncratic action of a pharmaceutical agent or
through drug–drug interactions. The two examples discussed
in this review highlight the signiﬁcant knowledge gaps that still
exist for many drugs and chemicals.
Drug action on an organism has both expected (eﬃcacious)
and unexpected (adverse) eﬀects. The elucidation of molecular
pathways involved in adverse events has only recently begun to
mature, resulting in the relatively late development of a target-
mediated view of toxicology. Biological pathways are man-
made constructs consisting of collections of signaling events.PPARs
differentiation/
proliferation
cell
migration
MMP/TIMP 
release
ERKSB203580
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ects of p38 on cell signaling involved in cellular regulation provide
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nistic search that may be in reach for the toxicologist. As such,
pathway toxicology is as an emerging ﬁeld of toxicology in the
post-genomic era that studies the molecular interactions be-
tween toxicant and biological pathways. It is based on the real-
ization that mechanism of toxicity is often not a result of
perturbation on a single biological target, but on multiple
nodes of molecular pathways within the host system.
This realization has several profound implications in the ﬁeld
of toxicology: (a) frank toxicity often occurs as a result of dys-
regulation of multiple molecular pathways; (b) genetic and epi-
genetic diﬀerences in key molecular pathways can modulate the
degree of a physiological response and therefore frank toxicity
in a host; (c) it may be possible to alleviate toxicity by modulat-
ing speciﬁc molecular pathways, as highlighted by the example
of diﬀerent sensitivity to acetaminophen-induced liver injury in
diﬀerent transgenic mice models. It is expected that our im-
proved knowledge of pathway toxicology can lead to important
revelations on the mechanisms of drug-induced organ injury
and innovative ways to prevent such injury.
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